Repherans noktası

Mart 2022 yayın taraması

Tedaviye özel yayınlar

Genel PH tedavisi

İlişkili PAH

1. Vlachou M et al. Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: A single-centre experience. Rheumatology (Oxford). 2022;61(3):1106-14. PMID:34142120.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (3)

2. Lee C et al. Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3). (Review) Respir Med. 2022 [Epub]. PMID:35334313.

3. Johnson SW et al. Variable monitoring of veterans with group 3 pulmonary hypertension treated with off-label pulmonary vasodilator therapy. Ann Am Thorac Soc. 2022 [Epub]. PMID:35312466.


4. Humbert M et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2022 [Epub]. PMID:35305871.



5. Huang Z et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty in patients with Takayasu arteritis and pulmonary hypertension. Front Immunol. 2022;13:828863. PMID:35359930.

6. Trofimov NA et al. Histological justification for the need of radiofrequency ablation of pulmonary arteries in patients with high-grade secondary pulmonary hypertension. Sovrem Tekhnologii Med. 2021;13(6):56-62. PMID:35265359.

7. Maarman GJ. Reviewing the suitability of mitochondrial transplantation as therapeutic approach for pulmonary hypertension in the era of personalised medicine. (Review) Am J Physiol Lung Cell Mol Physiol. 2022 [Epub]. PMID:35318860.


8. Zhang H et al. Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class. AsiaIntervention. 2022;8(1):58-68. PMID:35350791.

9. Guo F, Jing ZC. Beyond medications: Is pulmonary artery denervation the answer for pulmonary arterial hypertension?: PADN for PAH. (Editorial) AsiaIntervention. 2022;8(1):14-5. PMID:35355849.


10. de Perrot M et al. Outcome after pulmonary endarterectomy for segmental chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2022 [Epub]. PMID:35361492.

11. Ikeda N et al. Preprocedural frailty is strongly associated with symptoms after balloon pulmonary angioplasty. Glob Health Med. 2022;4(1):45-51. PMID:35291197.

12. Liu Z et al. Resting heart rate as a preoperative predictor of postoperative atrial fibrillation after pulmonary thromboendarterectomy. J Card Surg. 2022 [Epub]. PMID:35274764.

13. Zhang Y et al. Heart-rate recovery at 1 min after exercise predicts response to balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Front Cardiovasc Med. 2022;9:795420. PMID:35252384.

Pediatrik PH

14. Khalilian MR et al. Comparison of QT dispersion before and after PDA device closure in pediatrics. Ann Noninvasive Electrocardiol. 2022 [Epub]. PMID:35267238.

Etiyolojiye özel yayınlar

Pulmoner hipertansiyon

Genel PH

15. Ennala S et al. Effect of pulmonary artery catheter balloon inflation on pulmonary hemodynamics. Cardiovasc Diagn Ther. 2022;12(1):37-41. PMID:35282667.

16. Funk-Hilsdorf TC et al. Dysregulated immunity in pulmonary hypertension: From companion to composer. (Review) Front Physiol. 2022;13:819145. PMID:35250621.

17. Garcia MVF, Souza R, Caruso P. External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension. ERJ Open Res. 2022;8(1). PMID:35265704.

18. Goo HW, Park SH. Prediction of pulmonary hypertension using central-to-peripheral pulmonary vascular volume ratio on three-dimensional cardiothoracic CT in patients with congenital heart disease. Jpn J Radiol. 2022 [Epub]. PMID:35357627.

19. Jentzer JC et al. Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit. Eur Heart J Acute Cardiovasc Care. 2022;11(3):230-41. PMID:35064269.

20. Leong K et al. MRI feature tracking strain in pulmonary hypertension: Utility of combined left atrial volumetric and deformation assessment in distinguishing post- from pre-capillary physiology. Front Cardiovasc Med. 2022;9:787656. PMID:35369294.

21. Mai AS et al. Prevalence, risk factors and intervention for depression and anxiety in pulmonary hypertension: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9:765461. PMID:35252232.

22. Qutrio Baloch Z et al. Potential role of cardiopulmonary exercise testing as an early screening tool for patients with suspected pulmonary hypertension including exercise-induced pulmonary hypertension: Results from a retrospective analysis. Perm J. 2021;25. PMID:35348085.

23. Rawlings GH et al. Self-help cognitive behavioural therapy for anxiety in pulmonary hypertension: Pilot randomised controlled trial. ERJ Open Res. 2022;8(1). PMID:35265707.

24. Slivnick J et al. Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis. Open Heart. 2022;9(1). PMID:35246499.

25. Xue L et al. The spectrum and prevalence of arrhythmia in different clinical pulmonary hypertension groups in Chinese population. Clin Cardiol. 2022 [Epub]. PMID:35253244.

26. Culley MK, Chan SY. Endothelial senescence: A new age in pulmonary hypertension. (Review) Circ Res. 2022;130(6):928-41. PMID:35298304.

27. Lechartier B et al. Magnetic resonance imaging in pulmonary hypertension: An overview of current applications and future perspectives. (Review) Swiss Med Wkly. 2022;152:w30055. PMID:35262319.

28. Wang S et al. The role of glutamine and glutaminase in pulmonary hypertension. (Review) Front Cardiovasc Med. 2022;9:838657. PMID:35310969.

Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (Grup 5)

29. Ding XH et al. Baseline ratio of soluble Fas/FasL predicts onset of pulmonary hypertension in elder patients undergoing maintenance hemodialysis: A prospective cohort study. Front Physiol. 2022;13:847172. PMID:35299658.

30. Lentine KL et al. Incidence, clinical correlates, and outcomes of pulmonary hypertension after kidney transplantation: Analysis of linked US registry and Medicare billing claims. Transplantation. 2022;106(3):666-75. PMID:33859148.

Pediatrik PH

31. Wadia RS et al. Update on perioperative pediatric pulmonary hypertension management. (Review) J Cardiothorac Vasc Anesth. 2022;36(3):667-76. PMID:33781669.

Pulmoner arteriyel hipertansiyon (Grup 1)

Genel PAH

32. Badagliacca R et al. The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: Is risk of disease progression around the corner? Eur Respir J. 2022 [Epub]. PMID:35301247.

33. Badea R et al. Left main coronary artery compression by dilated pulmonary artery in pulmonary arterial hypertension: A systematic review and meta-analysis. Clin Res Cardiol. 2022 [Epub]. PMID:35290496.

34. Bernardo RJ et al. Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension: The Pulmonary Hypertension Association Registry. Ann Am Thorac Soc. 2022 [Epub]. PMID:35239467.

35. Ding J et al. Metabolomics-based mechanism exploration of pulmonary arterial hypertension pathogenesis: Novel lessons from explanted human lungs. Hypertens Res. 2022 [Epub]. PMID:35354935.

36. Eichstaedt CA et al. Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. Respir Res. 2022;23(1):74. PMID:35346192.

37. Gauthier-Loiselle M et al. Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data. Curr Med Res Opin. 2022 [Epub]. PMID:35243952.

38. Gu Y et al. (68)Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: A single-center, pilot study. J Nucl Cardiol. 2022 [Epub]. PMID:35322381.

39. Lefebvre B et al. Dual-energy CT lung perfusion characteristics in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PVOD/PCH): Preliminary experience in 63 patients.

Eur Radiol. 2022 [Epub]. PMID:35286410.

40. Li Q et al. Management of severe scoliosis with pulmonary arterial hypertension: A single-center retrospective case series study. Geriatr Orthop Surg Rehabil. 2022;13. PMID:35320992.

41. Maron BA, Humbert M. Finding pulmonary arterial hypertension –switching to offense to mitigate disease burden. JAMA Cardiol. 2022 [Epub]. PMID:35234810.

42. McCarthy BE et al. BMI and treatment response in patients with pulmonary arterial hypertension: A meta-analysis. Chest. 2022 [Epub]. PMID:35247393.

43. Park DH et al. Health disparities and differences in health-care-utilization in patients with pulmonary arterial hypertension. Front Psychiatry. 2022;13:813506. PMID:35280178.

44. Pinto VM et al. Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood. 2022;139(13):2080-3. PMID:34986266.

45. Wood JC. Pulmonary hypertension in thalassemia: A call to action. (Editorial) Blood. 2022;139(13):1937-8. PMID:35357479.

46. Quan R et al. Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry. Respirology. 2022 [Epub]. PMID:35293069.

47. Siniarski A et al. Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation. Platelets. 2022 [Epub]. PMID:35285383.

48. Stewart RH et al. Myocardial edema provides a link between pulmonary arterial hypertension and pericardial effusion. Circulation. 2022;145(11):793-5. PMID:35286166.

49. Su JY, Chen HF, Wang SM. Pregnancy outcome analysis of 94 patients with pulmonary arterial hypertension during pregnancy. Eur Rev Med Pharmacol Sci. 2022;26(6):1970-7. PMID:35363347.

50. Zozaya N et al. The economic burden of pulmonary arterial hypertension in Spain. BMC Pulm Med. 2022;22(1):105. PMID:35346140.

51. Calvier L, Herz J, Hansmann G. Interplay of low-density lipoprotein receptors, LRPs, and lipoproteins in pulmonary hypertension. (Review) JACC Basic Transl Sci. 2022;7(2):164-80. PMID:35257044.

52. Luna-López R, Ruiz Martín A, Escribano Subías P. Pulmonary arterial hypertension. (Review) Med Clin (Barc). 2022 [Epub]. PMID:35279313.

53. Ni S et al. Immune cells in pulmonary arterial hypertension. (Review) Heart Lung Circ. 2022 [Epub]. PMID:35361533.

54. Oliveira SD. Insights on the gut-mesentery-lung axis in pulmonary arterial hypertension: A poorly investigated crossroad. (Review) Arterioscler Thromb Vasc Biol. 2022 [Epub]. PMID:35296152.

55. Wu SH, Wu YJ. Regular risk assessment in pulmonary arterial hypertension - a whistleblower for hidden disease progression. (Review) Acta Cardiol Sin. 2022;38(2):113-23. PMID:35273432.

İdiyopatik PAH

56. Jang SY et al. A retrospective population-based survival study of idiopathic pulmonary arterial hypertension in Korea. J Korean Med Sci. 2022;37(10):e80. PMID:35289139.

57. Jones RJ et al. Autoimmunity is a significant feature of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2022 [Epub]. PMID:35316153.

İlişkili PAH

58. Amezcua-Guerra LM et al. Fibroblast growth factor 23 levels in pulmonary involvement associated with systemic sclerosis: A proof-of-concept study. J Rheumatol. 2022 [Epub]. PMID:35293330.

59. Bellan M et al. Increased levels of ICOS and ICOSL are associated to pulmonary arterial hypertension in patients affected by connective tissue diseases. Diagnostics (Basel). 2022;12(3). PMID:35328257.

60. Chiu SN et al. Pulmonary hypertension in adult congenital heart disease in Asia: A distinctive feature of complex congenital heart disease. J Am Heart Assoc. 2022 [Epub]. PMID:35285668.

61. Guillén-Del-Castillo A et al. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Sci Rep. 2022;12(1):5289. PMID:35347225.

62. Lai J et al. Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford). 2022;61(3):983-91. PMID:34057459.

63. Tan JS et al. Text mining-based drug discovery for connective tissue disease-associated pulmonary arterial hypertension. Front Pharmacol. 2022;13:743210. PMID:35370713.

64. Xiong A et al. Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: A systemic review and meta-analysis. Adv Rheumatol. 2022;62(1):10. PMID:35354494.

65. Zaaroor Levy M et al. MiRNAs in systemic sclerosis patients with pulmonary arterial hypertension: Markers and effectors. Biomedicines. 2022;10(3). PMID:35327430.

66. Ruaro B et al. An overview of different techniques for improving the treatment of pulmonary hypertension secondary in systemic sclerosis patients. (Review) Diagnostics (Basel). 2022;12(3). PMID:35328169.

Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (Grup 5)

67. Gupta R et al. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respir Med. 2022 [Epub]. PMID:35316723.

Pediatrik PAH

68. Awad A et al. Platelet activation markers in children with pulmonary arterial hypertension associated with congenital heart disease. Pediatr Cardiol. 2022 [Epub]. PMID:35234994.

69. Schäfer M et al. Repolarization dispersion is associated with diastolic electromechanical discoordination in children with pulmonary arterial hypertension. J Am Heart Assoc. 2022;11(6):e024787. PMID:35229614.

Sol kalp hastalığına bağlı PH (Grup 2)

70. Melzig C et al. Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease. Eur Radiol. 2022 [Epub]. PMID:35267088.

71. Pugliese NR et al. Exercise-induced pulmonary hypertension in HFpEF and HFrEF: Different pathophysiologic mechanism behind similar functional impairment. Vascul Pharmacol. 2022 [Epub]. PMID:35301117.

72. Verwerft J et al. Exercise systolic reserve and exercise pulmonary hypertension improve diagnosis of heart failure with preserved ejection fraction. Front Cardiovasc Med. 2022;9:814601. PMID:35224049.

73. Zhong XJ et al. Peak oxygen uptake is a strong prognostic predictor for pulmonary hypertension due to left heart disease. BMC Cardiovasc Disord. 2022;22(1):137. PMID:35361128.

74. Žvirblytė R et al. Echocardiographic predictors of exercise induced pulmonary hypertension in patients with asymptomatic moderate to severe mitral regurgitation and preserved left ventricular ejection fraction. Perfusion. 2022;37(2):188-97. PMID:33509060.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3)

75. Aurangabadkar GM et al. Evaluation of pulmonary hypertension in chronic obstructive pulmonary disease. Cureus. 2022;14(2):e21828. PMID:35291532.

76. He W et al. TIMP-1: A circulating biomarker for pulmonary hypertension diagnosis among chronic obstructive pulmonary disease patients. Front Med (Lausanne). 2021;8:774623. PMID:35284430.

77. Heresi GA et al. Identifying patients with group 3 pulmonary hypertension associated with COPD or ILD using an administrative claims database. Lung. 2022 [Epub]. PMID:35348836.

78. Jiang R et al. Echocardiography nomogram for predicting survival among chronic lung disease patients with severe pulmonary hypertension. J Clin Med. 2022;11(6). PMID:35329931.

79. Yogeswaran A et al. Relevance of cor pulmonale in COPD with and without pulmonary hypertension: A retrospective cohort study. Front Cardiovasc Med. 2022;9:826369. PMID:35252399.

80. Chai T et al. A narrative review of research advances in hypoxic pulmonary hypertension. (Review) Ann Transl Med. 2022;10(4):230. PMID:35280399.

81. Wu XG et al. Diagnostic value of computed tomography-based pulmonary artery to aorta ratio measurement in chronic obstructive pulmonary disease with pulmonary hypertension: A systematic review and meta-analysis. (Review) Clin Respir J. 2022 [Epub]. PMID:35289083.

82. Baldi BG, Souza R. Pulmonary hypertension in interstitial lung disease. (Editorial) Arch Bronconeumol. 2022 [Epub]. PMID:35312512.

KTEPH ve diğer pulmoner arter obstrüksiyonları (Grup 4)

83. Abdelnour-Berchtold E et al. Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure. J Heart Lung Transplant. 2022 [Epub]. PMID:35370035.

84. Benza RL et al. Application of the REVEAL risk score calculator 2.0 in the CHEST study. Respir Med. 2022 [Epub]. PMID:35256218.

85. Dering MR et al. Prevalence of mental disorders in patients with chronic thromboembolic pulmonary hypertension. Front Psychiatry. 2022;13:821466. PMID:35308878.

86. Le Pennec R et al. Lung ventilation/perfusion scintigraphy for the screening of chronic thromboembolic pulmonary hypertension (CTEPH): Which criteria to use? Front Med (Lausanne). 2022;9:851935. PMID:35321469.

87. Lepsy N et al. Childhood maltreatment, mental well-being, and healthy lifestyle in patients with chronic thromboembolic pulmonary hypertension. Front Psychiatry. 2022;13:821468. PMID:35280158.

88. Miao R et al. Examining the development of chronic thromboembolic pulmonary hypertension at the single-cell level. Hypertension. 2022;79(3):562-74. PMID:34965740.

89. Shahin Y et al. CMR measures of left atrial volume index and right ventricular function have prognostic value in chronic thromboembolic pulmonary hypertension. Front Med (Lausanne). 2022;9:840196. PMID:35360708.

90. Yamagata Y et al. Right ventricular dyssynchrony in patients with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Circ J. 2022 [Epub]. PMID:35283366.

91. An J et al. Acute pulmonary embolism and chronic thromboembolic pulmonary hypertension: Clinical and serial CT pulmonary angiographic features. (Review) J Korean Med Sci. 2022;37(10):e76. PMID:35289137.

Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (Grup 5)

92. Huitema MP et al. Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screening. Respir Med. 2022;195:106762. PMID:35227546.


93. Omarjee L et al. Performance of finger systolic blood pressure measurement to detect digital occlusive arterial disease in systemic sclerosis. Rheumatology (Oxford). 2022;61(3):1115-22. PMID:34142126.

94. Pellicano C et al. Maresin1 is a predictive marker of new digital ulcers in systemic sclerosis patients. Microvasc Res. 2022. PMID:35346718.

95. Scaturro D et al. Rehabilitative interventions for ischaemic digital ulcers, pain, and hand functioning in systemic sclerosis: A prospective before-after study. BMC Musculoskelet Disord. 2022;23(1):193. PMID:35236311.

96. Spinella A et al. Photobiomodulation therapy: A new light in the treatment of systemic sclerosis skin ulcers. Rheumatol Ther. 2022. PMID:35334095.

Hazırlama tarihi: Mayıs 2022